Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 1.00 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.77 |
| ▸ | HTR2B | P41595 | 2/20 | 0.77 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16774492 | 1.00 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL20122156 | 1.00 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL16774444 | 1.00 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL18352476 | 0.91 | ADORA3 (0.83) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL25566677 | 0.89 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1 | |
| SCHEMBL3740327 | 0.87 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL16774389 | 0.85 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL16774370 | 0.85 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2A | |
| SCHEMBL16774258 | 0.85 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2A | |
| SCHEMBL16774261 | 0.80 | ADORA3 (0.83) | ADORA3TMIGD3ADORA1ADORA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |